Gefitinib belongs to a group of medications known as tyrosine kinase inhibitors. Tyrosine kinases are naturally occurring proteins in the body that help regulate cell growth, among other things.
Gefitinib works by blocking the action of a specific tyrosine kinase known as epidermal growth factor receptor tyrosine kinase (EGFR-TK). EGFR-TK tells cancer cells to grow and divide. By blocking the action of EGFR, gefitinib may slow down or stop the growth of cancer tumors.
Clinical Effects for Gefitinib
Gefitinib has been studied in a variety of clinical trials for the treatment of non-small cell lung cancer. In one of these studies, 10.6 percent of people with non-small cell lung cancer had tumors that responded to gefitinib after failing at least two previous chemotherapy regimens. This study did not assess whether gefitinib improved survival.
In a study that evaluated the effect of gefitinib on survival, people with non-small cell lung cancer whose disease progressed despite previous treatment, or who could not tolerate previous treatment, were given either gefitinib or a placebo (a "sugar pill" that does not contain any active ingredients). People given gefitinib lived 5.6 months, while those who were given a placebo lived 5.1 months.
In two other studies, gefitinib was used in combination with standard first-line chemotherapy for the treatment of non-small cell lung cancer. In these studies, the addition of gefitinib did not extend the life of people who had not previously been treated with chemotherapy. It also did not provide any benefit in the time it took for the cancer to progress or how well the tumors responded to treatment.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Iressa [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP;2005 June.
Food and Drug Administration, Center for Drug Evaluation and Research. Drugs@FDA. FDA Approved Drug Products. FDA Web site. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed October 7, 2012.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click